Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Beximco Pharmaceuticals Limited is a leading generic and specialty pharmaceutical manufacturer based in Bangladesh, focusing on both domestic and international markets, including the US and Europe. The company differentiates itself through its extensive product portfolio, strong R&D capabilities, and a robust distribution network that enhances its competitive position in the pharmaceutical sector.
Beximco generates revenue primarily through the sale of generic pharmaceuticals, leveraging its cost-effective manufacturing processes and economies of scale. The company benefits from strong pricing power in emerging markets and a growing presence in regulated markets, allowing it to capture higher margins on specialty medications.
Regulatory approvals for new drug formulations in the US and EU markets
Changes in pricing regulations in key markets like Bangladesh and India
Expansion of product lines into high-demand therapeutic areas such as oncology and diabetes
Partnerships or collaborations with global pharmaceutical companies
Regulatory changes in pharmaceutical pricing and reimbursement policies
Technological disruption in drug development processes
Intense competition from both local and multinational pharmaceutical companies
Potential for market entry by generic competitors with lower pricing strategies
Low liquidity risk due to a current ratio of 4.13, but reliance on cash flow generation for ongoing investments
Potential currency risk from international sales and imports
moderate - Beximco's performance is somewhat linked to GDP growth in emerging markets, where healthcare spending tends to increase during economic expansions.
Interest rates have a minimal direct impact on Beximco's operations, but rising rates could affect consumer spending on healthcare products, indirectly influencing demand.
minimal - The company has a low debt-to-equity ratio of 0.05, indicating limited reliance on external financing.
growth - Investors are likely attracted to Beximco for its strong revenue growth and expansion into new markets.
moderate - The stock has shown historical volatility, but its strong fundamentals provide some stability.